Researchers from the U.S. National Cancer Institute (NCI) have developed a chemotherapy-free, targeted treatment regimen that leads to durable remissions in people with certain types of diffuse large B-cell lymphoma (DLBCL). The five-drug ViPOR regimen, named for its inclusion of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, synergistically targets multiple molecular…

BRAF mutated pediatric gliomas respond better to combination targeted therapy than chemotherapy, data just published in The New England Journal of Medicine affirms. The researchers found combination targeted therapy lessened chemotherapy side effects, improved overall response rate by more than four-fold, and increased median progression free survival from 7.4 months…

A combination of bacterial therapy with other treatment modalities may improve cancer treatment efficacy without additional toxicity, according to a report from Columbia Engineering researchers. They have developed a new approach for preclinical evaluation of bacterial therapies in lung cancer models. Using this approach, they were able to rapidly characterize…

A targeted therapy has significantly reduced relapse rates among children with high-risk Hodgkin’s lymphoma (HL) in a multicenter clinical trial. Patients who received the targeted antibody-drug conjugate (ADC) brentuximab vedotin (BV), with the standard chemotherapy regimen, were 10% less likely to relapse. The findings were published in the New England…

Combination PD-1/CTLA-4 blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in patients with BRAF V600 mutant metastatic melanoma. However, little prospective data existed to guide the choice of initial therapy or sequence in these patients. In a paper in the Journal of Clinical Oncology researchers conducting the DREAMseq…

On Friday, the U.S. Food and Drug Administration (FDA) approved trastuzumab-deruxtecan—sold under the brand name Enhertu—for the treatment of patients with unresectable or metastatic HER2-low breast cancer. Administered through IV infusion, the drug is the first approved therapy for patients with the newly identified HER2-low breast cancer subtype. The expanded…

Researchers have identified a metabolic enzyme and pathway in triple-negative breast cancer (TNBC) patients that they hope could serve as a biomarker to select patients for targeted therapy, including one drug, CPI-613, currently in trials for other cancers. Specifically, they found that high expression of dihydrolipoamide S-succinyltransferase (DLST), a tricarboxylic…

Sponsor: OmniSeq Roswell Park Comprehensive Cancer Center subsidiary OmniSeq and LabCorp jointly launched OmniSeq Advance, a single test that combines targeted therapy and immuno-oncology biomarkers. The test is the first New York State CLEP-approved assay to combine next-generation sequencing (NGS)-based comprehensive genomic profiling, tumor mutational burden (TMB) and microsatellite status…

The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP)—have updated their 2013 evidence-based guideline for the testing and treatment of patients with tyrosine kinase inhibitors (TKIs). The new guideline reflects the rapid pace of change in…

HTG Molecular Diagnostics today announced a master services agreement with Daiichi Sankyo and a research agreement with France’s Centre Léon Bérard, both covering separate projects to develop targeted therapies. The value of the agreements was not disclosed. The agreement with Daiichi Sankyo covers several projects to be performed for the…

Mitochondria play a crucial role as the powerhouses of cells, generating the energy necessary for cellular functions. For years, they have been seen as a promising target for anti-cancer therapies, yet their impermeable inner membrane has posed significant challenges. Now, Ohio State University scientists combined methods to administer gene therapy…

In a crucial Phase I/II trial, researchers at The University of Texas MD Anderson Cancer Center have reported significant success in treating patients with relapsed or refractory B-cell malignancies using cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting CD19. The findings, published in Nature Medicine, show…

Chemotherapy has at least two shortcomings: It can harm healthy cells as well as cancerous ones, and it can have difficulty reaching therapeutic targets that hide within cancer cells. To get around these shortcomings, biomedical engineers at Binghamton University collaborated with colleagues in China have found a method whereby cancer…

Researchers at City of Hope have developed a new targeted chemotherapy that shows promise against all solid tumor types, in preclinical studies. The new drug candidate, AOH1996, targets proliferating cell nuclear antigen (PCNA) a protein once that to be “undruggable” with early research showing that the targeted chemotherapy appears to…

The dominant paradigm in clinical oncology is personalized (therapeutic) medicine driven by precision diagnostics based on a solid foundation of basic and translational research in oncogenesis and signaling pathways.  It is recognized that malignant transformation occurs through the accumulation of somatic mutations with the ultimate evolution to a malignant tumor…